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Background: Carcinoma ex pleomorphic adenoma (CXPA) is an uncommon malignant tumor with highly
aggressive biological behavior. Our goal was to investigate the prognosis of CXPA in the major salivary glands and
factors influencing it.
Methods: We retrospectively reviewed 51 patients diagnosed with CXPA of the major salivary glands between
1999 and 2006, comprising 36 males and 15 females, aged from 23 to 86 years. All patients underwent surgery with
curative intention, and 21 received postoperative radiation therapy.
Results: Of the 51 patients, 39.2% developed locoregional recurrence and 27.5% developed distant metastases.
Median follow-up was 54 months. At the time of analysis, 29 (56.9%) patients were deceased. Overall survival was
62.7% at 3 years and 50.3% at 5 years. Tumor-specific survival was 64.4% at 3 years and 53.5% at 5 years. Using
chi-squared tests, invasiveness, T stage, lymph node involvement and clinical stage were found to be significantly
associated with locoregional recurrence. Histological grade, invasiveness, lymph node involvement and perineural
invasion were associated with distant metastases (P < 0.05). Cox analysis showed that T stage, lymph node
involvement, histological grade and perineural invasion were independent prognostic factors for overall survival.
Conclusion: T stage, lymph node involvement, histological grade, perineural invasion and extent of invasion are
important prognostic factors of CXPA in the major salivary glands. Surgery is the primary treatment modality for
CXPA and postoperative radiation therapy may be used in patients with factors for poor prognosis.
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The malignant form of pleomorphic adenoma (PA) (or
carcinoma ex pleomorphic adenoma (CXPA)), also called
malignant mixed tumor, carcinosarcoma or metastasizing
PA, is defined as a carcinoma arising from a primary or re-
current benign PA. Carcinosarcomas are composed of ma-
lignant epithelial and mesenchymal components, and are
therefore often called ‘true malignant mixed tumors’,
whereas metastasizing PAs are characterized by the pres-
ence of one or more foci of metastatic, histologically be-
nign PAs, but these two entities are exceedingly rare [1].
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reproduction in any medium, provided the orCXPA represent approximately 3% to 5% of all salivary
gland neoplasms and 5% to 15% of salivary gland malig-
nancies [2-5]. Misdiagnosis is common because the re-
sidual PA component may be small, and because various
carcinoma subtypes may be present [5,6]. Many studies
consider that CXPA is a highly malignant carcinoma
with poor prognosis, frequently leading to metastasis
and disease-related death. Previous studies identified
several clinicopathological factors with an unfavorable
correlation with CXPA prognosis, including advanced
stage, lymph node involvement, extent of invasion,
tumor type and grade [3,7,8]. Due to the condition’s low
incidence, no standard treatment has been described so
far. As for most other salivary gland malignancies, sur-
gery is the main treatment for CXPA, and postoperative
radiation therapy plays an important role in the currenttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gests that adjuvant chemotherapy can improve CXPA
prognosis.
This is a retrospective review of a single institution’s
experience. Unlike previous reports that included CXPA
in both major and minor salivary glands, which may in-
fluence the interpretation of results, our study focused
only on the major salivary glands, in which surgery was
used as the main curative-intention treatment for all pa-
tients. In addition, we had a relatively large series for this
uncommon disease. Our goal was to identify prognostic
variables that could help to better guide CXPA therapy.
Methods
Between January 1999 and June 2006, 61 patients with
CXPA of the major salivary glands were treated initially
in the Tumor Hospital of Zhejiang Province (China). Of
these, we excluded six patients with unresectable or
metastatic disease at presentation, three patients without
a follow-up in our hospital and one patient with a his-
tory of laryngeal carcinoma. All remaining 51 patients
had a pathologically confirmed CXPA, were treated in a
curative intention, and were therefore enrolled into this
retrospective study. The study was approved by the
hospital’s Ethics Committee. All patients were staged
(TNM) according to the American Joint Committee on
Cancer (AJCC) staging system, 7th edition. Tumors were
subclassified into three categories based on the WHO
criteria: non-invasive (the malignant component was
confined within the fibrous capsule of the PA), minim-
ally invasive (invasion beyond the capsule was 1.5 mm
or less) or invasive (invasion beyond the capsule was
greater than 1.5 mm). Initial diagnosis was performed by
a number of pathologists who worked at our hospital
during the study period. However, an experienced path-
ologist reviewed tumor tissue slides thoroughly for sub-
type determination, histological grade, proportion of
carcinomatous components, invasiveness and perineural
invasion. A consensus was reached between two pathol-
ogists in cases of inconsistencies between the initial
diagnosis and the review.
Statistical methods
Statistical analysis was performed using SPSS 13.0 (SPSS
Inc, Chicago, IL, USA). Follow-ups started from the date
of surgery and ended on 31 July 2012. Survival was de-
termined from the date of surgery to the time of death
using the Kaplan–Meier method. Patients lost to follow-
up were included in the survival analyses, but were con-
sidered as censored. Statistical differences in survival
curves were evaluated using the log-rank test. Multivari-
ate analyses were performed using the Cox proportional
hazard model. Categorical variables were tested using
chi-squared tests or Fisher’s exact tests, as appropriate.Statistical tests were two-sided and the level of signifi-
cance was 5%.Results
Patients’ and treatment characteristics
Table 1 summarizes the clinicopathological characteris-
tics. The study included 36 males and 15 females, for a
male-to-female ratio of 2.4:1. Their ages ranged from 23
to 86 years (median, 57 years). Being older (more than
55 years) was significantly correlated with higher disease
stage (P = 0.016). Of all tumors, 27 (52.9%) originated
from the parotid gland, 23 (45.1%) from the subman-
dibular gland and only one (2%) from the sublingual
gland. In the parotid gland, 13 (48.1%) tumors were lo-
cated in the deep lobe, while 14 (51.9%) were in the
superficial lobe. Ten (19.6%) patients had a previously
treated PA. The distribution of clinical stage was: 8
(15.7%) Stage I, 9 (17.6%) Stage II, 8 (15.7%) Stage III
and 26 (51.0%) Stage IV. Lymph node involvement was
observed in 17 (33.3%) patients, and perineural invasion
was discovered in 23 (45.1%) patients. Nine (17.6%) tu-
mors were non-invasive CXPA, 3 (5.9%) were minimally
invasive CXPA and 39 (76.5%) were invasive CXPA. The
histological grade was high in 17 (33.3%) tumors, inter-
mediate in 19 (37.3%) and low in 15 (29.4%). The carcin-
omatous component made up less than 50% of the mass
in 7 patients (13.7%) and greater than 50% in 44 (86.3%).
Table 2 shows the distribution of subtypes of malignant
components, with salivary duct carcinoma and myoepi-
thelial carcinoma as the most common (37.3% and 25.5%,
respectively).
All 51 patients underwent primary tumor resection. Of
the 27 patients with a tumor in the parotid gland, five
patients had superficial parotidectomy and 22 had total
parotidectomy; either total or partial resection of the in-
volved facial nerve was performed in 10 patients. The 23
patients with submandibular gland disease underwent
excision of the submaxillary gland, and the patient with
sublingual gland disease underwent excision of the
mouth floor. Resection of involved or suspiciously in-
volved adjacent structures (such as the skin or mandible)
was performed in ten patients. A total of 46 patients
underwent neck dissection, with modified radical neck
dissection in 25 patients (levels I to V) and selective
neck dissection (level I to III or IV) in 21 patients. Of
the 34 stage III/IV patients, 21 received postoperative ra-
diation therapy with an average irradiation dose of 60.2
Gy. Patients were recommended for radiation therapy if
they were stage III/IV; the reasons for not receiving radi-
ation therapy were because of the physician’s choice or
because the patient refused. Three patients received ad-
juvant chemotherapy because they had extensive and
multiple lymph node metastases.
Table 1 Clinical and histological characteristics of the
patients (n = 51)
Characteristics n Percentage





Parotid gland 27 52.9
Submandibular gland 23 45.1
Sublingual gland 1 2
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159 months). Three patients were lost to follow-up at
31, 67 and 121 months, respectively. Of all 51 patients,
27 (52.9%) patients experienced a recurrence or metastasis
during follow-up: 20 patients (39.2%) had locoregional
failure, 14 patients (27.5%) had distant metastases and
7 (13.7%) had both distant failure and locoregional failure.
By the end of follow-up, 29 (56.9%) patients were dead.
Locoregional recurrence
Of all the patients, 20 (39.2%) had a locoregional failure,
comprising 11 cases of local recurrence only, 5 cases of
lymph node recurrence only and 4 cases of local and lymph
node recurrence. Invasiveness (P = 0.01), T stage (P <
0.001), lymph node involvement (P = 0.008) and clinical
stage (P = 0.001) were significantly associated with loco-
regional recurrence (Table 3). Of the 12 patients with non-
or minimally invasive carcinoma, only one patient (8.3%)
experienced a locoregional failure, while 19 patients (48.7%)
had a locoregional failure in the invasive group (P = 0.012).
Nine patients (26.5%) without lymph node involvement
had a locoregional failure, while 11 patients (64.7%) with
lymph node involvement had a locoregional failure (P =
0.008). Locoregional recurrence rates in the T1/2 and T3/4
groups were 8.3% and 66.7%, respectively (P < 0.001).
Distant metastasis
Fourteen patients (27.5%) had distant metastases. The most
common site of distant failure was the lung (8 patients,Table 2 Distribution of malignant component subtypes of
CXPA
Subtype n Percentage
Salivary duct carcinoma 19 37.3
Myoepithelial carcinoma 13 25.5
Adenocarcinoma not otherwise specified 11 21.6
Adenoid cystic carcinoma 2 3.9
Oncocytic carcinoma 2 3.9
Squamous cell carcinoma 2 3.9
Mucoepidermoid carcinoma 1 2.0
Acinic cell carcinoma 1 1 2.0
Table 3 Influence of clinical and pathologic parameters on recurrence and survival
Variables P value
Locoregional recurrence Distant metastasis Tumor- specific survival Overall survival
Age (<55/≥55) 0.193 0.881 0.090 0.033
Sex 0.941 0.543 0.340 0.183
Primary site 0.361 0.318 0.893 0.650
(parotid/submandibular, sublingual)
Pleomorphic adenoma operation history (no/yes) 0.955 0.840 0.383 0.564
Malignant component (S/M/A/O)* 0.990 0.601 0.842 0.682
Histological grade 0.417 0.004 0.020 0.011
(low, intermediate/high)
Invasiveness 0.012 0.015 0.001 0.003
(non-invasive, minimally invasive/invasive)
Carcinomatous component 0.146 0.401 0.318 0.482
(<50%/>50%)
T stage (1, 2/3, 4) <0.001 0.712 0.002 0.004
Lymph node involvement 0.008 <0.001 <0.001 <0.001
(negative/positive)
Clinical stage 0.001 0.076 <0.001 <0.001
(I, II/III, IV)
Perineural invasion 0.086 0.020 <0.001 <0.001
(negative/positive)
Note: * S, Salivary duct carcinoma; M, Myoepithelial carcinoma; A, Adenocarcinoma not otherwise specified; O, Others.
Slashes mean comparison between the categorical variables in each side of slashes. Commas indicate the combination of the categories for comparison
with others.
Figure 1 Survival for all patients. (A) Overall survival. (B) Tumor-specific survival.
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siveness (P = 0.02), lymph node involvement (P < 0.001)
and perineural invasion (P = 0.02) were associated with dis-
tant metastases (Table 3). Metastasis rates were 14.7% in
the low/intermediate grade group and 52.9% in the high
grade group (P = 0.004). However, there was no difference
in the metastasis rates between low and intermediate grade
groups. No patients with non- or minimally invasive car-
cinoma experienced metastasis. Three patients (8.8%) with-
out lymph node involvement had a distant failure, while 11
patients (64.7%) with lymph node involvement had a dis-
tant failure (P < 0.001). For the patients with and without
perineural invasion, the metastasis rates were 43.5% and
14.3%, respectively (P = 0.02).Survival
At the time of the present analysis, 29 (56.9%) patients
were dead: 24 patients died from their cancer, while 5 pa-
tients died from other causes. Overall survival was 62.7%
at 3 years and 50.3% at 5 years. Tumor-specific survival
was 64.4% at 3 years and 53.5% at 5 years (Figure 1). In
univariate analyses, histological grade (P = 0.02), invasive-
ness (P = 0.001), T stage (P = 0.002), lymph node involve-
ment (P < 0.001), clinical stage (P < 0.001) and perineural
invasion (P < 0.001) were significantly associated with
tumor-specific survival. Factors significantly associated
with overall survival were age (P = 0.03), histological grade
(P = 0.01), invasiveness (P = 0.003), T stage (P = 0.004),
lymph node involvement (P < 0.001), clinical stage (P <
0.001) and perineural invasion (P < 0.001) (Table 3).
When the seven significantly associated variables in uni-
variate analyses were entered into a Cox model, T stage,
lymph node involvement, histological grade and perineural
invasion were identified as independent prognostic factors
for overall survival (Table 4, Figure 2).Discussion
In the present study, a male predominance was observed,
as in one large study of CXPA of major salivary glands [8],
although some reports showed a slight female predomin-
ance [7,11]. The median age of our patients was 57 years,
as in previous reports [7,8]. In our study, patients older
than 55 years had worse overall survival than patients
younger than 55 years. There are two possible reasons for
this. First, in our study, being older was associated with aTable 4 Multivariate analysis for overall survival of carcinoma
Variables Regression coefficient β Stand
T stage 0.693
Lymph node involvement 1.520
Histological grade 0.793
Perineural invasion 1.286higher disease stage. Secondly, older patients were more
likely to die of non-tumor causes.
CXPA is generally accepted as an aggressive malignancy,
with regional metastases being common, and with a high
mortality rate. However, survival rates in CXPA patients
may vary. In a review, Gnepp et al. found 5-year survival
ranged from 25% to 65% [2]. A recent review showed
5-year survival ranging from 30% to 75%. This difference
could be due to different stage distributions or different
proportions of intracapsular CXPA in their cohorts [3].
Among our 51 patients, 5-year overall survival was
50.3% and 5-year tumor-specific survival was 53.5%.
Locoregional recurrence and distant metastases were the
main reasons for failure. As expected, advanced T stage
and lymph node involvement were identified as important
factors for an unfavorable clinical outcome in our study.
We noted that only 1 of 17 patients with positive cervical
nodes did not experience recurrence or metastasis, and
that no patient was still alive 10 years after the initial ther-
apy. Our observation supports studies that considered
lymph node metastasis as the most important prognostic
factor for CXPA [12,13].
Based on the presence and extent of invasion of the car-
cinomatous component outside the fibrous capsule, CXPA
can be divided into non-invasive, minimally invasive or in-
vasive. Although non-invasive CXPA marks the beginning
of the malignant transformation, it tends to exhibit the
benign behavior of PA. All 14 patients with non-invasive
CXPA reported by Lewis et al., LiVolsi et al. and
Brandwein et al. had tumors that behaved in a benign
manner [6,12,14]. CXPA with extracapsular invasion can
be subdivided into minimally invasive or invasive, but
there is confusion in the literature about the extent of
extracapsular invasion that distinguishes minimally inva-
sive from invasive disease. Olsen and Lewis noted that the
extent of invasion beyond the fibrous capsule ranged from
2 to 100 mm, with a mean of 24 mm, and that patients
with invasion <5 mm had a benign clinical course [8].
Tortoledo et al. observed that all patients with >8 mm of
invasion died from their disease, whereas none with
<8 mm of invasion died [15]. Brandwein et al. found no
recurrence in patients with tumor invasion of <1.5 mm
[14]. Despite these contradictions, the current WHO
classification considers 1.5 mm as the cutoff for minim-
ally invasive CXPA [1]. In our study, none of the 12 pa-
tients with minimally invasive or non-invasive CXPAex pleomorphic adenoma
ard error P value Relative risk 95% CI
0.273 0.011 1.999 1.170–3.414
0.424 <0.001 4.574 1.993–10.497
0.257 0.002 2.210 1.336–3.658
0.494 0.009 3.620 1.375–9.529
Figure 2 Overall survival. (A) Overall survival according to T stage. (B) Overall survival according to lymph node metastases. (C) Overall survival
according to histological grade. (D) Overall survival according to perineural invasion.
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their tumor. The extent of invasion was found to correlate
with CXPA recurrence and survival in our study. However,
invasiveness was not identified as an independent prog-
nostic factor for overall survival in multivariate analyses,
but this may be due to the fact that three cases with min-
imally invasive or invasive CXPA died of other reasons.
Lüers et al. [7] observed that 23% of their patients suf-
fered from facial palsy. In the series studied by Olsen and
Lewis, facial nerve involvement was present in approxi-
mately one-third of the cases [8], which revealed that
CXPA frequently involves nerves. However, there are few
studies on the influence of perineural invasion on the prog-
nosis of CXPA. In our series, 10 (37.0%) of 27 patients with
CXPA located in the parotid gland had facial paralysis.Moreover, we observed that perineural invasion of CXPA
was prevalent on histopathological examination, reaching
41.2%. In our study, perineural invasion had a statistically
significant effect on distant metastases, tumor-specific sur-
vival and overall survival (P < 0.05), and had a tendency to
be associated with locoregional recurrence (P = 0.086). In
multivariate analyses, perineural invasion was identified as
an independent prognostic factor for overall survival.
In line with previous reports [8,11], our data also
showed that histological grade ranked highly among the
predictors of CXPA outcome. High-grade tumors in our
series were more likely to predict unfavorable clinical
outcomes, such as poor survival and metastases.
Most types of salivary epithelial carcinomas have been
reported as malignant components of CXPA, and the
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carcinoma was thought to be the most common type
[6,7]. In our series, the most frequent subtype was salivary
duct carcinoma, followed by myoepithelial carcinoma.
Katabi et al. [11] reported that the presence of myoepi-
thelial carcinoma subtype appeared to increase the risk of
recurrence. However, histological subtype was not found
to be a prognostic factor in our study, as with the 73 cases
studied by Olsen and Lewis [8].
CXPA is composed of PA and carcinoma in different
proportions. In some cases, the malignant component can
completely replace the mixed tumor, which usually leads
to misdiagnosis. In our series, the carcinomatous compo-
nent made up more than 50% of the cancer in the majority
of cases (86.3%), as found by Lewis et al. [6]. However, un-
like Lewis et al., the carcinomatous component was not a
prognostic factor in our series, but this may be due to the
small number of patients in the <50% group.
However, these observations might suffer from limita-
tions. First, CXPA is a rare condition, and our results
are therefore limited by the relatively small number of
patients. Second, performing several univariate analyses
increases the probability of error. However, to overcome
this, we included the factors identified using univariate
analyses in a multivariate analysis.
Surgery is currently the primary treatment for CXPA
[3,9]. In our opinion, the extent of surgery must be indi-
vidualized on the basis of the tumor location and the in-
volvement of adjacent structures. For instance, for parotid
neoplasms, total or radical parotidectomy is indicated for
frankly invasive CXPA, and the facial nerve should be
resected if directly involved by the tumor. However, super-
ficial parotidectomy can be used for some early tumors lo-
calized in the superficial lobe. Because a third of our
patients were confirmed to have positive lymph nodes by
postoperative pathology and because the rate of occult
metastases could be even higher, which predicts a poor
outcome, we recommend that neck dissection should be
performed for the majority of CXPA patients, except for
some intracapsular or minimally invasive diseases.
As with most other salivary gland malignancies, post-
operative radiation therapy was often used as an adju-
vant therapy in patients with adverse risk factors [7,10].
However, due to the condition’s low incidence, there are
few studies on the specific role of radiotherapy on
CXPA. Chen et al. retrospectively analyzed 63 CXPA
patients and observed that the use of postoperative
therapy significantly improved local control, but that it
did not translate into a survival advantage [13]. In our
center, postoperative radiotherapy was usually used for
CXPA with advanced stage, high histological grade,
lymph node involvement and perineural invasion, while
surgery alone may be a therapy option for small carcin-
omas. However, more studies are necessary to determinewhich patients can really benefit from postoperative
radiotherapy.
Conclusions
T stage, lymph node involvement, histological grade,
perineural invasion and extent of invasion are important
prognostic factors of CXPA in the major salivary glands.
Surgery is the primary treatment modality for CXPA and
postoperative radiation therapy may be used in patients
with factors for poor prognosis.
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